{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T01:58:25Z","timestamp":1768787905960,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004473","name":"Sakarya University","doi-asserted-by":"publisher","award":["2020-9-33-52"],"award-info":[{"award-number":["2020-9-33-52"]}],"id":[{"id":"10.13039\/501100004473","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.molimm.2021.12.007","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T17:10:33Z","timestamp":1639242633000},"page":"280-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The relationship between the efficacy of talazoparib and the functional toll-like receptors 3 and 9 in triple negative breast cancer"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-9914","authenticated-orcid":false,"given":"Gamze","family":"Guney Eskiler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3248-4279","authenticated-orcid":false,"given":"Asuman","family":"Deveci \u00d6zkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molimm.2021.12.007_bib0005","doi-asserted-by":"crossref","first-page":"11087","DOI":"10.1007\/s11033-012-2013-1","article-title":"Toll-like receptor 3: implications for proinflammatory microenvironment in human breast cancer","volume":"39","author":"Amarante","year":"2012","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.molimm.2021.12.007_bib0010","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3389\/fimmu.2019.01176","article-title":"Direct inhibition of IRF-dependent transcriptional regulatory mechanisms associated with disease","volume":"10","author":"Antonczyk","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molimm.2021.12.007_bib0015","doi-asserted-by":"crossref","first-page":"287","DOI":"10.18632\/oncoscience.474","article-title":"Translating the role of PARP inhibitors in triple-negative breast cancer","volume":"6","author":"Beniey","year":"2019","journal-title":"Oncoscience"},{"key":"10.1016\/j.molimm.2021.12.007_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/716564","article-title":"Expression of toll-like receptors on breast tumors: taking a toll on tumor microenvironment","volume":"2012","author":"Bhattacharya","year":"2012","journal-title":"Int. J. Breast Cancer"},{"key":"10.1016\/j.molimm.2021.12.007_bib0025","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/nm.2830","article-title":"Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape","volume":"18","author":"Bidwell","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.molimm.2021.12.007_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/23723556.2019.1585170","article-title":"Beyond DNA repair: the novel immunological potential of PARP inhibitors","volume":"6","author":"Chabanon","year":"2019","journal-title":"Mol. Cell. Oncol."},{"key":"10.1016\/j.molimm.2021.12.007_bib0035","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/08923973.2020.1725040","article-title":"Anti-inflammatory effects of nobiletin on TLR4\/TRIF\/IRF3 and TLR9\/IRF7 signaling pathways in prostate cancer cells","volume":"42","author":"Deveci Ozkan","year":"2020","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.molimm.2021.12.007_bib0040","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1101\/gad.334425.119","article-title":"The impact of PARPs and ADP-ribosylation on inflammation and host\u2013pathogen interactions","volume":"34","author":"Fehr","year":"2020","journal-title":"Genes Dev."},{"key":"10.1016\/j.molimm.2021.12.007_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-10-665","article-title":"Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis","volume":"10","author":"Gonz\u00e1lez-Reyes","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.molimm.2021.12.007_bib0050","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1002\/jcp.29552","article-title":"Talazoparib nanoparticles for overcoming multidrug resistance in triple\u2010negative breast cancer","volume":"235","author":"Guney Eskiler","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.molimm.2021.12.007_bib0055","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22678","article-title":"Proteomic analysis of talazoparib resistance in triple\u2010negative breast cancer cells","volume":"35","author":"Guney Eskiler","year":"2021","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.molimm.2021.12.007_bib0060","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/eji.201545867","article-title":"Synergistic inhibition of PARP\u20101 and NF\u2010\u03baB signaling downregulates immune response against recombinant AAV2 vectors during hepatic gene therapy","volume":"46","author":"Hareendran","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.molimm.2021.12.007_bib0065","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/cmi.2018.4","article-title":"TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy","volume":"15","author":"Huang","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.molimm.2021.12.007_bib0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe4434","article-title":"PARP inhibitors unleash the antitumor immune response","volume":"12","author":"Ileana-Dumbrava","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molimm.2021.12.007_bib0075","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920944116","article-title":"PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers","volume":"12","author":"Lee","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.molimm.2021.12.007_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0784-8","article-title":"Prospects for combining immune checkpoint blockade with PARP inhibition","volume":"12","author":"Li","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.molimm.2021.12.007_bib0085","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-3-030-35582-1_5","article-title":"Toll-like receptors signaling in the tumor microenvironment","volume":"1223","author":"McCall","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.molimm.2021.12.007_bib0090","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1158\/1541-7786.MCR-06-0007","article-title":"Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity","volume":"4","author":"Merrell","year":"2006","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.molimm.2021.12.007_bib0095","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1080\/08923973.2020.1797779","article-title":"Toll-like receptor (TLR) gene expression and immunostimulatory effect of CpG oligonucleotides in hormone receptor positive cell line T47D and triple negative breast cancer cell line MDA-MB-468","volume":"42","author":"Natarajan","year":"2020","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.molimm.2021.12.007_bib0100","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ctrv.2018.04.010","article-title":"The role of PARP inhibition in triple-negative breast cancer: unraveling the wide spectrum of synthetic lethality","volume":"67","author":"Papadimitriou","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.molimm.2021.12.007_bib0105","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3390\/cancers12061502","article-title":"Combined PARP inhibition and immune checkpoint therapy in solid tumors","volume":"12","author":"Peyraud","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.molimm.2021.12.007_bib0110","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1158\/1078-0432.CCR-12-0408","article-title":"Molecular pathways: toll-like receptors in the tumor microenvironment\u2014Poor prognosis or new therapeutic opportunity","volume":"19","author":"Ridnour","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molimm.2021.12.007_bib0115","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.4049\/jimmunol.176.8.4894","article-title":"TLR3 can directly trigger apoptosis in human cancer cells","volume":"176","author":"Salaun","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.molimm.2021.12.007_bib0120","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/eji.200737744","article-title":"Toll\u2010like receptors\u2019 two\u2010edged sword: when immunity meets apoptosis","volume":"37","author":"Salaun","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.molimm.2021.12.007_bib0125","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1158\/0008-5472.CAN-10-3490","article-title":"TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer","volume":"71","author":"Salaun","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.molimm.2021.12.007_bib0130","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3389\/fimmu.2014.00330","article-title":"Toll-like receptor 9 in breast cancer","volume":"5","author":"Sandholm","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molimm.2021.12.007_bib0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21037\/cco.2016.12.01","article-title":"PARP inhibitor and platinum agent in triple negative breast cancer: utilizing innovative trial design to bring together something\u201c new\u201d and something\u201c old\u201d","volume":"6","author":"Sharma","year":"2017","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.molimm.2021.12.007_bib0140","first-page":"786","article-title":"Expression profile of Toll\u2011like receptors in human breast cancer","volume":"21","author":"Shi","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.molimm.2021.12.007_bib0145","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.3390\/cells9092040","article-title":"The role of PARP1 in monocyte and macrophage commitment and specification: future perspectives and limitations for the treatment of monocyte and macrophage relevant diseases with PARP inhibitors","volume":"9","author":"Sobczak","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.molimm.2021.12.007_bib0150","doi-asserted-by":"crossref","first-page":"432","DOI":"10.15761\/ICST.1000183","article-title":"Toll-like receptors and breast cancer","volume":"3","author":"Sun","year":"2016","journal-title":"Integr. Cancer Sci. Therap."},{"key":"10.1016\/j.molimm.2021.12.007_bib0155","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10549-012-2181-7","article-title":"Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer","volume":"135","author":"Tuomela","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.molimm.2021.12.007_bib0160","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3727\/096504016X14756226781802","article-title":"Overexpression of interferon regulatory factor 7 (IRF7) reduces bone metastasis of prostate cancer cells in mice","volume":"25","author":"Zhao","year":"2017","journal-title":"Oncol. Res."}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589021003461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589021003461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T13:42:39Z","timestamp":1758980559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589021003461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":32,"alternative-id":["S0161589021003461"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2021.12.007","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The relationship between the efficacy of talazoparib and the functional toll-like receptors 3 and 9 in triple negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2021.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}